



PATIENT-FOCUSED DRUG DEVELOPMENT
GUIDANCE PUBLIC WORKSHOP

**Methods to Identify What is
Important to Patients
&
Select, Develop or Modify
Fit-for-Purpose Clinical Outcomes
Assessments**

Workshop Date: October 15-16, 2018

1
2 **Discussion Document for Patient-Focused Drug Development Public**
3 **Workshop on Guidance 2:**

4 **METHODS TO IDENTIFY WHAT IS IMPORTANT TO**
5 **PATIENTS**

6

7	TABLE OF CONTENTS	
8	I. INTRODUCTION	4
9	A. OVERVIEW AND SCOPE	5
10	B. QUESTIONS FDA HAS IDENTIFIED FOR THE OCTOBER WORKSHOP	6
11	II. METHODS TO IDENTIFY WHAT IS IMPORTANT TO PATIENTS	7
12	A. Methodological Overview	7
13	1. Concept Elicitation	7
14	B. Developing the Research Objectives and Questions	7
15	1. Burden of Disease/Treatment and Benefits and Risks (Harms) in Disease Management	8
16	III. QUALITATIVE RESEARCH METHODS	9
17	A. Sources of Qualitative Data to Elicit Burden of Disease and Treatment Benefits	
18	and Risks	10
19	1. Best practices for use of qualitative sources	13
20	IV. QUANTITATIVE RESEARCH METHODS	23
21	A. Sources of Quantitative Data to Elicit Burden of Disease/Treatment and Benefits	
22	and Risks	23
23	1. Best practices for use of quantitative sources	23
24	V. MIXED METHODS	29
25	VI. CONCLUSIONS	29
26	VII. REFERENCES	30
27		

28 **TABLE OF TABLES**

29 Table 1. Overview of Content..... 5
30 Table 2. Considerations for Researchers for Framing Research Questions and Objectives Related
31 to Disease/Treatment Burden and Benefits and Risks (Harms) in Disease Management 8
32 Table 3. Advantages and Disadvantages of Different Qualitative Data Collection Methods 10
33 Table 4. Considerations for Selecting Qualitative Methods for Participants..... 13
34 Table 5. Types of Interview Methods 14
35 Table 6. Advantages and Disadvantages of Different Interview Modes 15
36 Table 7. Types of consensus panels 21
37 Table 8. Advantages and Disadvantages of Open- and Close-ended Questions 26
38 Table 9. Different Types of Response Options..... 27
39

40 I. INTRODUCTION

41
42 FDA recognizes the need to obtain meaningful *patient input*¹ to understand their experience with
43 their disease and its treatment to inform development of endpoint measures to assess clinical
44 outcomes of importance to patients and caregivers in medical product development. To ensure a
45 *patient-focused* approach to medical product² development and regulation, FDA will develop
46 guidance on methods to identify what matters most to patients to be measured in clinical trials,
47 specifically, how to design and implement studies to capture the patient’s voice in a robust
48 manner. This document has been developed to support the Patient-Focused Drug Development
49 Guidance: Methods to Identify What is Important to Patients and Select, Develop or Modify Fit-
50 for-Purpose Clinical Outcome Assessments public workshop³ discussions that will inform
51 guidance development.

52
53 This workshop will address the second in a series of four methodological *patient-focused drug*
54 *development* (PFDD) guidance documents⁴ that FDA is developing to describe in a stepwise
55 manner how stakeholders (patients, researchers, medical product developers and others) can
56 collect and submit *patient experience data* and other relevant information from patients and
57 *caregivers* for medical product development and regulatory decision making.

58
59 Guidance 1⁵ covers the selection of patients from whom to collect information (e.g., sampling
60 methods for collecting representative information on patient experience. Guidance 2 will focus
61 on methods to elicit relevant information from patients⁶, in particular how their disease affects
62 their daily lives, what they find most troublesome, and the challenges, problems, and burdens of
63 the treatments for the disease. Some of these issues were introduced in Guidance 1, but will be
64 covered in greater depth in Guidance 2.

65
66 The discussion document for the Guidance 2 workshop presents a more in-depth discussion of:

- 67
- 68 • Methods for eliciting information from patients and other stakeholders, specifically
69 gathering information about what aspects of *symptoms*, impacts of their disease, and
70 other issues are important to patients;
 - 71 • Common pitfalls in collecting information from patients that can lead to results that
inadequately or incompletely identify what is important to patients; and

¹ The Glossary defines many of the terms used in this discussion document. Words or phrases found in the Glossary appear in bold italics at first mention.

² A drug, biological product, or medical device.

³ <https://www.fda.gov/Drugs/NewsEvents/ucm607276.htm>

⁴ The four guidance documents that will be developed correspond to commitments under section I.J.1 associated with PDUFA VI under Title I of the FDA Reauthorization Act of 2017. The projected timeframes for public workshops and guidance publication reflect FDA’s published plan aligning the PDUFA VI commitments with some of the guidance requirements under section 3002 of the 21st Century Cures Act. <https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm563618.pdf>

⁵ *Draft Guidance for Industry, FDA, and Other Stakeholders Patient-Focused Drug Development: Collecting Comprehensive and Representative Input*

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM610442.pdf>

⁶ When referencing patients, we are including other stakeholders.

- Operational details including development of interview guides, selection of types of survey questions, and considerations for collecting demographics and survey information, which are provided in appendices to this document.

A. OVERVIEW AND SCOPE

For ease of navigation through this document, the content is organized into three parts:

- Methods to identify what is important to patients
- Approaches to asking the right questions (in qualitative and quantitative research settings)
- Best practices in how to do qualitative and quantitative research (operationalization)

An overview of the content presented in this document is shown in [Table 1](#).

Table 1. Overview of Content

	Topic	Section
Methods to Identify What Is Important to Patients	What types of research methods can be used to identify what is important to patients?	Section IIA
	How do you identify what is important to patients?	Section IIA.1
	How do you frame questions to capture patients' experience with the burden of disease and/or treatment?	Section IIB.1
	How do you frame questions to capture patients' experience on treatment benefits and risks in the management of their disease?	Section IIB.2
	What types of qualitative methods can be used to talk to patients?	Section IIIA
	What types of quantitative methods can be used to obtain patient input?	Section IVA Appendix 7
Asking the Right Questions	How to avoid inappropriate framing of questions when talking to patients (e.g., leading/judging questions)?	Section IIIA.1(i)
	What types of questions do you ask in a survey?	Section IVA.1(i)
	How to avoid inappropriate framing of questions in surveys (e.g., priming)?	Section IVA.1(i)
	How to talk to special patient populations (pediatrics, cognitively impaired, rare diseases) and different cultures?	Appendix 2
	How to survey special patient populations and different cultures?	Appendix 5
Best Practices in How to Do Qualitative and Quantitative Research	How to design and implement qualitative studies?	Appendix 1
	What are the relevant study materials needed for: <ul style="list-style-type: none"> Qualitative studies (e.g., interview/discussion guides)? Survey studies? 	Appendix 1 Appendix 4

	Topic	Section
(Operationalization)	How to design and implement studies for different types of settings (observational, screening/exit interviews)? <ul style="list-style-type: none"> • Qualitative studies • Quantitative studies 	Appendix 3 Appendix 6
	How to design and implement quantitative studies (e.g., surveys, other technologies)?	Appendix 4 Appendix 7

85

86 **B. QUESTIONS FDA HAS IDENTIFIED FOR THE OCTOBER WORKSHOP**

87

88 With this discussion document FDA seeks input from patient stakeholders, researchers, medical
89 product developers, and others on how best to communicate FDA’s current thinking on
90 approaches to collecting patient experience data. Questions for readers to consider for Guidance
91 2:

- 92 1. Identify best practices (qualitative and quantitative methods) for eliciting information
93 about what aspects of symptoms, impacts of disease, and other issues important to
94 patients that are representative of the target population of patients and caregivers. What
95 level of detail of the methodology do you think is appropriate for this guidance?
96
- 97 2. What sample size will elicit sufficient information about the patient experience to assure
98 *representativeness* but is feasible?
99
- 100 3. What other data (e.g., data from social networks, accelerometry, room surveillance) can
101 be used to elicit or derive information about the patient experience in a feasible manner?
102
- 103 4. Use of social media is recognized as a potential data collection method to elicit
104 information regarding patient experience.
105 a. Will information collected from social media sources meet the goals of Guidance
106 2 (e.g., collecting representative information on important symptoms, burdens,
107 and related issues)? If yes, how do we determine the adequacy of data from social
108 media sources?
109 b. Is there a need for patient verification if social media is the data collection method
110 to elicit information about the patient experience?
111
- 112 5. Important considerations are needed for special populations, such as pediatrics, the
113 cognitively impaired, and rare diseases. What other special populations (beyond
114 pediatric, cognitively impaired, and rare diseases) should be identified for this FDA
115 Guidance? Are there any other factors to consider when eliciting information from
116 special populations?
117
- 118 6. The level of rigor needed for generating patient experience data can vary across studies
119 and will depend on the intended use. However, there are certain elements common to all
120 studies such as a protocol, structured data collection, and analysis. How much detail
121 about each aspect would be useful in guidance? On a website? Elsewhere?

- 122 7. What document structure and content would be most useful for this guidance?
123
- 124 8. Many potential research methods are available and not all could be included in the
125 discussion document. Is it clear the Agency is open to discussion of the methods
126 described and other methods, both within medical product programs and in the pre-
127 competitive space?
128
- 129 9. What are the most important timepoints when FDA input could be maximally helpful?

130 II. METHODS TO IDENTIFY WHAT IS IMPORTANT TO PATIENTS

131 A. Methodological Overview

132

133 *What types of research methods can be used to identify what is important to patients?* FDA
134 recommends using *qualitative*, *quantitative*, or *mixed methods* to collect robust and meaningful
135 patient experience data, which includes the *disease and treatment burden* and *benefits* and *risks*
136 in management of the patient’s disease. For details on the important distinctions between these
137 methodological approaches refer to [Table 2 of Guidance 1](#).

138 Qualitative and quantitative methods can be categorized by the depth of information (e.g.,
139 descriptive information) they provide and the extent to which they collect information that may
140 be more generalizable to the *target population*. When selecting an appropriate research method,
141 you should ideally balance the importance of depth versus *generalizability*, or use a mixed
142 method approach to get a combination of both.

143 1. Concept Elicitation

144

145 Concept elicitation is a process to collect a holistic set of relevant *concepts* (e.g. disease and
146 treatment symptoms and associated impacts) that are important to patients. Concepts can be
147 elicited using qualitative, quantitative, or mixed methods (See [Sections III](#), [IV](#) and [V](#)).

148 Concept elicitation should occur in a wide range of patients with the disease of interest and/or
149 other stakeholders such as *patient representatives*, caregivers and clinicians to represent
150 variations in severity and in demographic characteristics such as age, sex, ethnicity, education,
151 and language groups in accordance with the anticipated study design to obtain representative
152 input from the underlying target patient population.

153 B. Developing the Research Objectives and Questions

154

155 Research objectives and questions should be clearly stated so that the data collected from
156 patients meets the intended use of the information. Research objectives and questions should be
157 specific, clearly defined and reflect the scientific and regulatory goals of the study. A discussion
158 of how to define research objectives and questions can be found in [Section IIB of Guidance 1](#).

159 The research objectives should determine the questions to be addressed to the patient group, the
 160 methods to be implemented, and the appropriate target population.

161
 162 Questions to ask yourself when determining the target population include but are not limited to
 163 the following:

- 164 • What are the potential barriers for patients created by inclusion and exclusion criteria?
- 165 • What is the impact of exclusion criteria on the enrollment of particular subpopulations?
- 166 • Does the study design and methodology impact representation of subpopulations in a
 167 study?

168 *1. Burden of Disease/Treatment and Benefits and Risks (Harms) in Disease Management*
 169

170 *How do you frame questions to capture patients experience with the burden of disease/*
 171 *treatment and benefits and risks in disease management?* [Table 2](#) lists some important
 172 considerations that can serve as the foundation for research objectives and questions intended to
 173 capture the patient experience related to disease/ treatment burden and benefits and risks in
 174 disease management.

175 **Table 2. Considerations for Researchers for Framing Research Questions and Objectives**
 176 **Related to Disease/Treatment Burden and Benefits and Risks (Harms) in Disease**
 177 **Management**

Patient Experience	Considerations	Example Questions/Objectives
Burden of Disease	<ul style="list-style-type: none"> • Patient perspective on burden of disease • Caregiver perspective on patient’s burden of disease • Frequency and/or severity of symptoms • Impact of disease symptoms on functioning in patients’ daily lives • Symptoms that require treatment or reaching out to doctor • Symptoms most important to improve with treatment 	<ul style="list-style-type: none"> • Which disease symptoms are most important to patients? • Which impacts of disease symptoms are most important to patients? • Which symptoms are most burdensome to patients?
Burden of Treatment	<ul style="list-style-type: none"> • Patient perspective on burden of treatment • Impact on participation in activities (e.g., work and school) • Caregiver perspective on patient’s burden of treatment • Patient experiences (positive/negative) with a mode of administration of a treatment (e.g., subcutaneous vs. intravenous infusion, oral vs. subcutaneous) 	<ul style="list-style-type: none"> • Which aspects of treatment burden are most important to patients?

Patient Experience	Considerations	Example Questions/Objectives
	<ul style="list-style-type: none"> • Treatment frequency (e.g., daily vs. weekly) • Time to administer treatment • Treatment storage (e.g., refrigeration, room temperature) • Special treatment administration (e.g., treatment administered only at hospital/clinic) 	
Benefits and Risks	<p>Patient perspective on:</p> <ul style="list-style-type: none"> • Frequency of treatment side effects • Severity of treatment side effects • Ideal <i>treatment outcome</i> (resolution of symptoms, relief of symptoms, increased survival) • Efficacy of prior treatment(s) (<i>treatment effects</i>) • Ideal treatment • Convenience of treatment (including frequency of dosing regimen, ease of use, route of administration) • Treatment satisfaction • Treatment adherence • Impact on participation in activities (e.g., work and school) 	<ul style="list-style-type: none"> • How much did a patient improve in their symptoms or impacts while on treatment? • What treatment benefits are most important to patients? • What treatment benefits did the patient expect to experience? Did the patient's experience align to what he/she expected? • What treatment side effects (risks/harms) are of most concern to patients? • Are patients willing to experience the treatment side effects to achieve treatment benefit?

178

179 III. QUALITATIVE RESEARCH METHODS

180

KEY MESSAGES
<ul style="list-style-type: none"> • Identify the appropriate participants to talk to (i.e., patients with condition of interest) • Determine a sufficient number of participants to talk to • Use an experienced and well-trained facilitator (e.g., interviewer, moderator) to lead interviews or discussions • Use a semi-structured interview/discussion guide with well-designed questions to get better insights from participants, as the facilitator's choice of words can affect the participants' input or behavior. • Use a balanced mix of open-ended and structured/pre-determined probing questions

181

182 **A. Sources of Qualitative Data to Elicit Burden of Disease and Treatment Benefits and**
 183 **Risks**
 184

185 *What types of qualitative methods can be used to talk to patients?* Qualitative research methods
 186 can generate in-depth information about the experiences, perspectives, and feelings (including
 187 needs and priorities) of patients and other individuals (e.g., clinicians, caregivers), in their own
 188 words. These include but are not limited to:

- 189 • Interviews ([Section III.A.1\(i\)](#))
- 190 • Focus groups ([Section III.A.1\(ii\)](#))
- 191 • Consensus panels (Delphi) ([Section III.A.1\(iii\)](#))
- 192 • Observations ([Section III.A.1\(iv\)](#))
- 193 • Social Networks ([Appendix 7](#))
- 194 • Patient-focused drug development (PFDD) meetings (FDA or externally-led)⁷

195
 196 Qualitative methods can be useful for achieving the following research goals:
 197

- 198 • Eliciting information regarding which disease-related concepts (e.g. signs, symptoms and
 199 impacts) are important to patients
- 200 • Determining research and drug development program priorities based on the patient
 201 experience
- 202 • Gaining a more in-depth understanding of disease or treatment burden in order to develop
 203 clinical trial *endpoints*

204 [Table 3](#) lists some advantages and disadvantages of using different methods of gathering
 205 qualitative data. [Section III.A.1](#) will provide further detail on each method.
 206

207 **Table 3. Advantages and Disadvantages of Different Qualitative Data Collection Methods**

Qualitative Research Method	Advantages	Disadvantages
<i>One-on-One Interviews</i>	<ul style="list-style-type: none"> • Can gain in-depth information on the topic of interest and/or understanding of how a respondent interprets a question • Flexible – can tailor interviews to generate more or less detailed information based on research needs • Interviews can generate can 	<ul style="list-style-type: none"> • Timing (e.g., length of interviews; number of patients interviewed) • Data interpretation can be influenced by subjective interpretation • Studies can be expensive

⁷ <https://www.fda.gov/drugs/developmentapprovalprocess/ucm579400.htm>

Qualitative Research Method	Advantages	Disadvantages
	<p>generate rich, nuanced data about an individual's experience and perspectives</p> <p>robust data for analysis</p>	
<i>Focus Groups</i>	<ul style="list-style-type: none"> • Can gain in-depth information on the topic of interest and/or understanding of respondents' question interpretation • Saturation can be obtained sooner with focus groups than with one-on-one interviews. • Elicit feedback from multiple participants at one time • Participants more likely to provide candid responses • Participants can build on each other's ideas • Relatively inexpensive 	<ul style="list-style-type: none"> • Individual data might not be available from each participant • May not be efficient in covering maximum depth on a particular issue • Distractions or peer-pressure may emerge within the group • Single individuals might dominate the conversation and multiple perspectives may not be shared • Group setting may inhibit some individuals from providing sensitive information • Large volumes of qualitative data might be difficult to analyze • Data analysis can be influenced by subjective interpretation • Less flexibility in scheduling can present recruitment challenges
<i>Consensus Panels (Delphi)</i>	<ul style="list-style-type: none"> • Acceptable method for reaching consensus among appropriate experts and stakeholders on important issues and topics • Anonymous process, when appropriate, reduces the role of ego and interpersonal issues in reaching consensus 	<ul style="list-style-type: none"> • Lack of universal guidelines for process • Size of expert panel should be considered as it is difficult to achieve consensus among a larger group • Implications for lack of anonymity in the case of modified Delphi panel methods • Definitions of "expert" opinion is variable • No clear standards for the most acceptable level of consensus

Qualitative Research Method	Advantages	Disadvantages
<i>Observations of Patient Behavior or Events (rating from a video observation)</i>	<ul style="list-style-type: none"> • Low burden for participants as the observation is non-invasive and does not require active participation • Advantages of naturalistic settings/real-world context 	<ul style="list-style-type: none"> • Less common because it may be time-consuming and logistically cumbersome to execute if conducted in natural settings (e.g., study environments may vary across locations) • Some concepts and experiences are not observable • Can be expensive • Participant behavior may be affected by observer presence • Observational environments, if in naturalistic settings, may be variable and affect the reliability and generalizability of the results
<i>Social Networks</i>	<ul style="list-style-type: none"> • See Table 6 of Appendix 7 for advantages of social networks 	<ul style="list-style-type: none"> • See Table 6 of Appendix 7 for disadvantages of social networks
<i>PFDD Meetings</i>	<ul style="list-style-type: none"> • See advantages of focus groups 	<ul style="list-style-type: none"> • Input is limited to patients who can attend the meeting which may minimize generalizability of findings to the target population • See disadvantages of focus groups

208
209
210
211
212
213
214
215
216
217
218
219

You should consider various factors when selecting the source of qualitative data to use, including but not limited to:

- Research purpose
- Target population
- Sample size (projected based on knowledge of the target patient population and in consultation with expert stakeholders)
- Study design
- Feasibility factors (e.g., research environment, cost of execution within the context of study budget, willingness and ability of patients to participate)
- Time
- Geography

220 [Table 4](#) lists some other participant factors to consider when selecting the most appropriate
221 qualitative method.

222 **Table 4. Considerations for Selecting Qualitative Methods for Participants**

Respondent Burden
<ul style="list-style-type: none">• Length of discussion<ul style="list-style-type: none">○ Consider sessions that are shorter in duration (e.g., 30-90 minutes each), when possible.• Travel<ul style="list-style-type: none">○ Determine whether remote alternatives (e.g., video-conferencing or telephone conferencing) can be used in lieu of in-person sessions.• Access to technology<ul style="list-style-type: none">○ Consider respondent accessibility to technology during study design; accommodations should be made accordingly to the extent possible to those with limited access.
Disease Progression
<ul style="list-style-type: none">• Patient and caregiver availability<ul style="list-style-type: none">○ Consider patient's disease status and level of care required when determining recruitment targets as this may impact study recruitment and retention.

223

224 *1. Best practices for use of qualitative sources*

225

226 The following sections outline general considerations related to each qualitative method.
227 Additional details regarding considerations for special populations and different cultures can be
228 found in **Appendix 2**.

229

230 i. Interviews

231

232 Interviews are the most common source of qualitative data in which a conversation between a
233 research participant and interviewer is directed toward producing information about participants'
234 experiences, feelings, and opinions and subsequently deriving meaning out of what participants
235 say. Interviews are useful for gathering in-depth information around a topic or to further
236 investigate the meaning attributed to questionnaire responses.

237

238 There are different types of interviews, which include:

239

- Semi-structured interviews

240

- Structured interviews

241

- Open-ended interviews

242 [Table 5](#) outlines different types of interview methods that can be used to generate qualitative
243 data on the patient experience.

Table 5. Types of Interview Methods

Type of Interviews	Description
<i>Semi-structured interviews</i>	<ul style="list-style-type: none"> • Most common method. • Using a semi-structured interview guide, the semi-structured interview allows the same general areas of information to be collected from each interviewee while still allowing a degree of flexibility and adaptability to help generate in-depth information from each participant based on their responses. • Interviewer sets the discussion agenda; the participant's responses help guide the level of information generated about the predetermined topics and their relative importance (Johnson and Christensen 2017).
<i>Structured interviews</i>	<ul style="list-style-type: none"> • Less common method. • Require the same open-ended questions to be asked of all participants, with no deviation. This approach facilitates faster interviews that can be more easily analyzed and compared. • A closed, fixed-response interview is a type of structured interview that requires each participant to be asked the same questions and asked to choose answers from among the same set of alternatives. This format is useful for those not practiced in interviewing; however, this method does not allow room for exploration and additional probing based on participant responses.
<i>Open-ended Interviews</i>	<ul style="list-style-type: none"> • Less common method. • Not led by predetermined questions. In order to remain as open and adaptable as possible, the dialog between the interviewer and participant remains open to the emergent priorities of the participant within the conversation. During the discussion, the interviewer provides little direction toward an <i>a priori</i> research agenda. • Although useful for generating in-depth responses, this type of interviewing is more time consuming in the analysis phase than other methods and may not be ideal for capturing information targeted toward specific research questions.

247 You should select an interview type to meet the needs of your study, taking into account the
 248 following:

- 249 • Target population, including disease characteristics (disease severity, rate of progression),
 250 clinical characteristics (phenotype, genotype), and demographics (e.g., age)
- 251 • Topic sensitivity (e.g., patients may be less open to discuss topics related to sexual
 252 functioning or mental health)
- 253 • Topic complexity (e.g., complex concepts might require more structured probes)

254
 255 For sensitive topics, it will be important to use a trained and seasoned qualitative interviewer
 256 who can:

- 257 • Create a safe environment
- 258 • Build rapport
- 259 • Be patient and allow the respondent to gather their thoughts, control their emotions, and
 260 find the words to describe their experience.
- 261 • Use creative qualitative interventions or techniques

262
 263 Once you have selected the interview method, you should also consider the mode or method of
 264 interview administration. Interviews can be administered in different modes/methods, which
 265 includes administration by:

- 266 • In-person
- 267 • Telephone
- 268 • Video Conference/Online [including web-based or webcam]
- 269 • Audio Computer-Assistance

271 The advantages and disadvantages of each interview mode/method are listed in [Table 6](#).

272 **Table 6. Advantages and Disadvantages of Different Interview Modes**

Interview Mode	Advantages	Disadvantages
<i>In-Person Interviews</i>	<ul style="list-style-type: none"> • Researchers can conduct each interview in a controlled environment (e.g., central facility) or in a location convenient to participants • Allows for collection of both verbal and non-verbal responses to help inform data interpretation 	<ul style="list-style-type: none"> • Time-consuming • Studies can be expensive • Scheduling and other logistical constraints (e.g., travel expenses) can limit participation
	<ul style="list-style-type: none"> • Can be implemented more rapidly than in-person interviews • Can provide an opportunity for including patients who 	<ul style="list-style-type: none"> • Unable to assess non-verbal cues (e.g., eye contact, body language, and level of distraction) to help inform an

Interview Mode	Advantages	Disadvantages
<i>Telephone Interviews</i>	<p>would otherwise not be able to participate in an in-person interview due to location, disease/condition, or level of impairment</p> <ul style="list-style-type: none"> • Participants may be more comfortable providing more personal information when they are not face-to-face with the interviewer 	<p>interviewer's interpretation of participant responses</p> <ul style="list-style-type: none"> • May be difficult to establish rapport between the interviewer and participant • Some participants have limited access to telephones; this should be taken into account when determining if telephone interviews are appropriate • Participants may dislike the intrusion of a call to their home or personal telephone line; may not have a private space to feel comfortable completing the interview • When telephone interviews are being conducted in a participant's home, disruptions (e.g., background noise and presence of family members) can interfere with sound quality and cause distractions
<i>Video Conference or Online Interviews (e.g., web-based or webcam)</i>	<ul style="list-style-type: none"> • Can be implemented more rapidly than in-person interviews • Can provide an opportunity for including patients who would otherwise not be able to participate in an in-person interview due to location, disease/condition, or level of impairment • Allows the interviewer to collect verbal and non-verbal responses 	<ul style="list-style-type: none"> • Some participants have limited access to computers and other video or online conferencing equipment (e.g., web cams) and software; studies should supply participants with necessary video or online conferencing equipment and software when personal devices are unavailable • Participants might not feel comfortable with video or online interviews • When video or online conferencing is being conducted in a participant's home, disruptions (e.g., background noise and presence of family members) can interfere with sound quality and cause distractions

274 When the interview type and mode/method of administration is determined, you should consider
275 the following:

- 276 • Number of interviews to conduct
- 277 • Design interview questions and interview guide
- 278 • Interviewer training and expertise
- 279 • Sites to recruit participants (number of sites, geographic and patient representation)

280

281 Number of interviews is dependent upon multiple factors, including but not limited to:

- 282 • Study design
- 283 • Disease or condition (e.g., rare disease, heterogenous disease)
- 284 • Study population (e.g., demographics)
- 285 • ***Concept saturation***

286

287 The study setting can also vary in which an interview is administered. The interview can be
288 administered outside of a clinical trial (observational study) or within a clinical trial (screening or
289 exit interview). See **Appendix 3** for considerations for these different types of qualitative
290 studies.

291

292 ***How do you avoid inappropriate framing of questions when talking to patients?*** The way
293 interview questions are framed is critical to ensure unbiased ***patient input***. When you ask
294 questions to patients you want to learn more about the patient's experience with their disease and
295 treatment. Leading questions (e.g., questions that includes or implies the desired answer to the
296 question in the phrasing of the question itself) are problematic as they result in biased or
297 false/misleading answers (results). It also is a missed opportunity to hear an unexpected insight.

298

299 Some ways to avoid asking leading questions include:

- 300 • Use a semi-structured interview guide with set of prepared questions (do not rephrase
301 questions in your own words)
- 302 • Design neutral questions to the extent possible
- 303 • Do not suggest an answer
- 304 • Do not assume you know how the participant is feeling

305

306 Other types of questions that may cause challenges to reliability of participants' responses
307 include:

- 308 • Questions that cast judgment on a participant's belief or choice
- 309 • Questions that are too broad, particularly, when asking about an abstract/complex
310 concept(s)

311 While follow-up/probing questions can help explore a topic further and provide clarification and
312 more details on participants' responses, the frequent use of probing questions, specifically
313 unstructured probing questions, can potentially introduce bias (e.g., mining data to affirm
314 interviewer's own ideas).

315

- 316 A good probing question includes but is not limited to the following:
- 317 • Is clear and concise
 - 318 • Allows for multiple responses
 - 319 • Avoids yes/no responses
 - 320 • Stimulates reflective thinking

<p>Examples:</p> <p><i>Example of a leading question</i></p> <p><i>“Do you consider it important to engage in daily exercise?”</i></p> <p>This question guides the respondent to respond in a more favorable or preferred answer. To prevent any misleading, this question could be changed to ask:</p> <p>“How often do you think you should exercise in a week to maintain a healthy lifestyle?”</p>
<p><i>Example of a question that casts judgment</i></p> <p><i>“Could you tell me why you are not treating your child’s autism?”</i></p> <p>This question implies that the interviewer is potentially casting judgment on the participant’s beliefs or choices. To minimize any perceived judgment, this question could be changed to ask:</p> <p>“Tell me what you think is the ideal course of treatment for your child’s autism.”</p> <p>Qualitative interviewers should adopt a non-judgmental attitude to avoid interviewer bias and maintain a positive relationship with the interviewee.</p>
<p><i>Example of a question asking about an abstract or complex concept</i></p> <p><i>“How satisfied were you receiving treatment through infusion?”</i></p> <p>Satisfaction is an abstract or complex concept since it is multidimensional. To obtain more meaningful information about this concept, direct specific questions may need to be asked to understand what elements go into an individual’s satisfaction:</p> <p>“Think about the last time you were at the clinic receiving your infusion. Please describe your infusion experience.”</p> <p>“What did you like or not like about your infusion experience?”</p> <p>“What parts of the infusion experience do you feel impacts your satisfaction rating for the treatment?”</p>

Examples of probing:

Scenario: A participant is being asked about benefits and risks of their treatments. The initial questions from the interviewer is:

What specifically about this treatment makes it the best?

The participant provides a very ambiguous response. Pre-determined focused probes may be needed to further explore the participant’s thoughts on the treatment. For example:

- Method of administration for the treatment
- Treatment dosing regimen
- Treatment side effects.

Some examples of how to frame probing questions for qualitative research interviews can be:

- “Tell me more about that.”
- “And how did you feel about that?”
- “What do you mean when you say [xxx]?”
- “What was your expectation for the treatment?”

321 ii. Focus Groups

322

323 Focus group interviews are carefully planned discussions conducted among a small group of
324 participants, led by a trained moderator. Focus group discussions are designed to elicit
325 information regarding participants’ experiences, feelings, and perspectives on a certain topic.
326 Group dynamics in focus groups can facilitate additional insights that one-on-one interviews
327 cannot; participant responses often prompt additional dialogue that would not otherwise occur
328 between an interviewer and participant in a one-on-one setting. Similar to interviews, framing of
329 questions for focus group discussions are important (see [Section IIIA.1\(i\)](#)).

330

331 Special considerations for focus groups include the following:

332

- 333 • Number of focus groups to conduct
- 334 • Sample size

335 As a general guideline, you should plan to conduct 3-4 focus groups, initially. However, the
336 number of focus groups may vary based on the following:

- 337 • Complexity of the topic(s) being discussed (e.g., all versus some impacts of a disease on
338 multiple dimensions of a patient’s quality of life);
- 339 • Heterogeneity of the participant sample, and
- 340 • Number of ***subgroups*** you plan to elicit information from (e.g., different age groups,
341 disease severity groups).

342 After conducting your focus groups, you should evaluate the data and determine whether
343 additional sessions are necessary to cover topics sufficiently (i.e., saturation) given the
344 heterogeneity of the patients.

345 In addition to determining the number of focus groups to conduct, you should consider the
346 sample size for each focus group to ensure you include the appropriate number of participants.
347 While it has been suggested that a reasonable number of participants in a focus group lies
348 between 5 and 10 patients they often range from 4 to 12 patients, although a larger group (e.g.,
349 between 10 and 12 patients) may make it difficult to generate rich responses from each
350 participant (Krueger & Casey, 1988). Ultimately, it is important to keep the group small enough
351 to enable the elicitation of in-depth responses from each participant but large enough for you to
352 get a wide variety of perspectives across different severity levels and demographic representation
353 within the target disease. A group may become fragmented (e.g., multiple, simultaneous
354 conversations occur) when it exceeds 12 participants, decreasing the likelihood of engagement
355 and responses from each individual.

356 Factors to consider when determining the appropriate sample size for a focus group include:

- 357 • **Study purpose.** If the purpose of your focus group is to elicit information regarding
358 symptoms and disease characteristics, more participants may be useful in a highly
359 heterogeneous condition for a detailed discussion and to adequately cover the concept. If
360 the purpose of the focus group is to cognitively debrief on a measure or pilot test a
361 measure, more participants will be required to generate sufficient data.
362
- 363 • **Complexity of the topic.** The more complex the condition or topics you want to discuss,
364 the fewer participants you want to enroll per group.
365
- 366 • **Number of probing questions you want to cover.** More questions, fewer people per
367 group.
368
- 369 • **Participant characteristics.** Focus group participants ought to be representative.
370 Participants should reasonably represent the target patient population intended for a
371 planned clinical trial or appropriate referent group so that results from the focus group
372 interviews can be as generalizable as possible.
373

374 iii. Consensus Panels (Delphi)

375
376 The Delphi Panel technique is a multi-stage survey process with the intent to achieve consensus
377 among experts on an important topic or issue; they can provide valuable data to help describe a
378 phenomenon. There are many different Delphi methods that can generate consensus data.
379 Different Delphi panel techniques and characteristics are presented in [Table 7](#).

380

381 **Table 7. Types of consensus panels**

Delphi Panel Technique	Characteristics
<i>Classical Delphi</i>	<ul style="list-style-type: none"> • Uses an open first round to facilitate idea generation to elicit opinion and gain consensus • Uses three or more rounds • Can be administered by paper (by postal mail), email, or online (see eDelphi below)
<i>Modified Delphi</i>	<ul style="list-style-type: none"> • Modification usually takes the form of replacing the first round with face-to-face interviews or a focus group or having a face-to-face meeting for the last session. • May use fewer than three rounds • Can be administered by paper (by postal mail), email, or online
<i>Decision Delphi</i>	<ul style="list-style-type: none"> • Usually adopts the same process as Classical Delphi • Focuses on making decisions rather than coming to consensus
<i>Policy Delphi</i>	<ul style="list-style-type: none"> • Uses expert opinion to come to consensus and agree on future policy related to a given topic
<i>Real Time Delphi</i>	<ul style="list-style-type: none"> • Usually adopts a similar process to Classical Delphi except experts may be in the same room • Consensus is reached in real-time rather than by postal mail • Sometimes referred to as a consensus conference
<i>e-Delphi</i>	<ul style="list-style-type: none"> • Usually adopts a similar process to Classical Delphi but is administered by email or online web survey
<i>Technological Delphi</i>	<ul style="list-style-type: none"> • Similar to the Real-time Delphi but uses technological devices (e.g., handheld keypads) allowing experts to respond to questions immediately while the technology calculates the mean or median response among panel members. This allows for instant feedback and a chance for experts to recast their votes in light of the group opinion when moving toward consensus
<i>Online Delphi</i>	<ul style="list-style-type: none"> • Usually adopts the same process as Classical Delphi however, questionnaires are completed and submitted online.
<i>Argument Delphi</i>	<ul style="list-style-type: none"> • Focused on the production of relevant factual arguments • A derivative of the Policy Delphi • A form of Delphi where there may be no consensus
<i>Disaggregative Delphi</i>	<ul style="list-style-type: none"> • Goal of consensus is not adopted • Conducts various scenarios of the future for discussion • Uses cluster analysis to process the data and facilitate interpretation

382 **Source:** Keeney et al., 2010

383
384 iv. Observations
385

386 Observational research methods, while not common, can also be used to generate meaningful
387 patient experience data. These methods could be useful in the following scenarios:

- 388 • Patients who experience episodic behavior that cannot be observed in a controlled
389 environment.
- 390 • Assessment of event and behavioral progression over extended periods of time (e.g.,
391 document changes in irregular behaviors that deviate from the norm – like aggressive
392 behaviors or confusion and behaviors observed in elderly Alzheimer’s patients).

393 In these cases, researchers can observe patients in real-time to generate data related to symptoms
394 or daily life functioning.

395 The different types of observations that are relevant to evaluating burden of disease and
396 treatment, as well as management of patient’s disease and burden of treatment include:

- 397 • **Participant as observer.** The researcher is a member of the group being studied, and the
398 group is aware of the research activity. For example, a researcher who is a patient
399 advocate and also a patient themselves, who observes naturalistic behaviors of fellow
400 patients in a community setting. Disclosure of their role as a researcher to participants is
401 given in advance for transparency.
- 402 • **Observer as participant.** The researcher is not a member of the group being studied and
403 identifies his/her researcher role to the group. For example, a researcher collecting data
404 without direct involvement with participants.
- 405 • **Complete observer.** The researcher is neither seen nor noticed by the group under study
406 and the group is unaware of being observed. For example, a researcher observing an
407 interview at a research facility (via two-way mirrors) or through live-streamed video.

408 Observations of individuals or groups often can be done to supplement interviews (individual or
409 group) by documenting cues from the environment and behaviors. Data from observations can be
410 useful in generating confirmatory evidence, used to complement more common elicitation
411 methods (e.g., one-on-one interviews) in the following ways:

- 412 • Confirm definitions of terms that participants use in interviews.
- 413 • Capture non-verbal cues (e.g., facial expressions, gestures, tone of voice, and other non-
414 verbal indicators) that are important for conceptual interpretation.
- 415 • Provide contextual information for specific disease or treatment experiences.
- 416 • Observe events that participants may be unable or unwilling to share (e.g., socially
417 unacceptable behaviors like aggression).
- 418 • Observe the duration of episodic events reported by patients in interviews or focus
419 groups.

420 Some disadvantages of observations can be that they are time consuming and may require
421 observers to receive special training on discerning significant from trivial observations. Refer to
422 **Appendix 3** for additional details regarding considerations for observational data collection.

423

424 **IV. QUANTITATIVE RESEARCH METHODS**

425

KEY MESSAGES

- Identify the appropriate participants to survey (i.e., patients with condition of interest)
- Determine a sufficient number of participants to survey
- Design a survey with specific, well-designed, and well-understood questions and adequate response options

426

427 **A. Sources of Quantitative Data to Elicit Burden of Disease/Treatment and Benefits and** 428 **Risks**

429

430 *What types of quantitative methods can be used to obtain patient input?* Quantitative research
431 methods are characterized by the collection of quantifiable data (e.g., numerical data) and the
432 application of statistical methods to summarize the collected data. There are different
433 quantitative approaches or sources to gather information related to the burden of disease and
434 treatment; and benefits and risks in patients' disease management, which include but not limited
435 to:

- Surveys/questionnaires
- Other technologies (e.g., social networks, accelerometry, room surveillance) (**Appendix 7**)

439 The use of surveys/questionnaires can be a quantitative approach to gather information related to
440 the burden of disease and treatment and benefits and risks in patients' disease management.
441 However, surveys/questionnaires can also be a qualitative approach depending on the type of
442 questions being used (see [Section IVA.1\(i\)\(b\)](#)).

443 *1. Best practices for use of quantitative sources*

444

445 The following sections outline general considerations related to survey methods. Details
446 regarding considerations for special populations and different cultures can be found in **Appendix**
447 **5**.

448 *i. Surveys/questionnaires*

449

450

451 There are two components in designing a survey/questionnaire:

- 452 • Deciding what to measure
- 453 • Designing and testing questions including instructions and response options

454

455 a. Deciding what to measure

456

457 ***What types of questions do you ask in a survey?*** For the assessment of burden of disease and
458 treatment and benefits and risks in patients' disease management, you will need to consider what
459 aspects of these objectives that you want to measure in a question. See [Section IIB](#).

460

461 b. Designing and testing questions

462

463 ***How to avoid inappropriate framing of questions in surveys?***

464 Designing a good survey/questionnaire involves:

- 465 • Selecting or designing questions that match the research objective(s) (see [Section IIB](#))
- 466 • Designing clear questions specific to the content of interest (e.g., disease symptoms and
467 impacts, current treatment, past treatments, treatment side effects)
- 468 • Designing questions that are interpreted and understood well by participants (e.g.,
469 questions should be designed for an appropriate reading level and use minimal clinical
470 terminology)
- 471 • Testing questions to make sure they can be answered as intended
- 472 • Placing the questions in a format to maximize the ease of use for respondents and
473 interviewers

474

475 Questions for surveys/questionnaires can be generated from multiple sources, which include but
476 not limited to the following (Streiner, Norman & Cairney, 2015):

- 477 • Literature
- 478 • Clinical observation
- 479 • Patients (e.g., focus groups, interviews)
- 480 • Expert opinion (e.g., interviews, Delphi panel)
- 481 • Theory
- 482 • Research

483

484 Patients living with the disease are the ideal source of information to generate questions for a
485 survey/questionnaire to evaluate burden of disease and treatment benefits and risks.

486

487 When designing questions for surveys/questionnaires, you should design questions to be good
488 measures to maximize the relationship between the answers recorded and what you are trying to
489 measure. The goal of a good measure is to increase the reliability of the question to ensure
490 consistent measurement across respondents (e.g., patients, caregivers, clinicians) (Flower, 2002).

491

492 A good question has the following characteristics:

- 493 • Questions mean the same thing to every respondent
- 494 • Questions are scripted, if administered by an interviewer

- 495 • Response options are appropriate and meaningful and communicated consistently to all
496 respondents

497

498 Key considerations to increase the reliability of respondents' answers to questions:

- 499 • Identify potential respondents
- 500 • Use natural and familiar language
- 501 • Avoid using incomplete questions (e.g., Age?, Reason last saw doctor?)
- 502 • Avoid poor wording of questions (e.g., poorly defined terms)
- 503 • Avoid using double-barreled or multi-barreled questions (i.e., a question that asks two or
504 more concepts at once)
- 505 • Avoid using double negatives (i.e., a sentence that includes two negatives)
- 506 • Avoid leading questions (see [Section IIIA.1\(i\)](#))

Examples:

Example of a double-barreled sentence

How embarrassed or self-conscious have you been because of your condition?

This question is asking two different concepts or issues:

1. How embarrassed have you been because of your condition?
2. How self-conscious have you been because of your condition?

Each of these two concepts may offer a different feeling from a respondent, and combining them into one question makes it unclear which feeling is being measured. Once a respondent answers the question, it will be impossible to know which concept the respondent was thinking about when they answered the question (unless it was an interviewer-administered question).

Example of a double negative sentence

Do you agree or disagree with the following statement?

Doctors should never be allowed not to discuss urgent lab results with patients on weekends.

If you disagree, you are saying that you do not think that doctors **should not** discuss urgent lab results to patients on the weekends. In other words, you probably believe that doctors should discuss urgent lab results to patients on the weekends.

If a negative item is in fact needed for a survey/questionnaire, you should underline the negative word or words to catch the participant's attention.

507

508

509 Questions can elicit different types of data, which include:

- 510 • **Nominal** data (also known as categorical variables) (e.g. sex, race, ethnicity)
- 511 • **Ordinal** data (e.g. disease severity of none, mild, moderate, severe; symptom frequency
- 512 of never, sometimes, always)
- 513 • **Continuous** data (e.g. age, BMI, fever temperature)

514
515 Questions used in surveys/questionnaires can be classified in two different groups, which also

516 applies to questions being asked in interviews:

- 517
- 518 • Closed-ended questions (questions with fixed set of response options)
- 519 • Open-ended questions (questions without a fixed set of responses options, e.g., free text)

520

521 **Table 8** lists examples of closed- and open-ended questions, as well as the advantages and

522 disadvantages of using different question types.

523 **Table 8. Advantages and Disadvantages of Open- and Close-ended Questions**

Question Type	Examples	Advantages	Disadvantages
Closed-ended questions	<i>Which of the following health conditions do you currently have?</i> <ul style="list-style-type: none">○ Asthma○ Acne○ High blood pressure○ Glaucoma	<ul style="list-style-type: none">• Respondent can more reliably answer the question when response options are given• Researcher can more reliably interpret the meaning of answers• Easier and quicker for respondents to record answers	<ul style="list-style-type: none">• May not provide respondent with a comprehensive list of response options• Response options may not be applicable to the respondent
Open-ended questions	<i>What health conditions do you have?</i>	<ul style="list-style-type: none">• May obtain answers that were unplanned• May obtain more realistic answers• Provides opportunity for respondents to answer questions in their own words• May be more appropriate when the list of possible answers is lengthy	<ul style="list-style-type: none">• May produce rare answers that cannot be analyzed in a useful manner

524

525 You should select the type of question for your survey/questionnaire based on the type of data

526 you would like to have for the results of your study. In some instances, it may be valuable to use

527 both open and closed-ended questions to collect both qualitative and quantitative data.

528
 529 When considering responses to questions, it is important to consider the kinds of possible
 530 responses that may arise. You should provide acceptable response options for the question being
 531 asked (e.g., method by which responses will be obtained). The response options for the questions
 532 may be determined by the content of question asked.

533
 534 [Table 9](#) lists some examples of the different types of response options and their potential
 535 limitations.

536 **Table 9. Different Types of Response Options**

Response Option Type	Examples	Potential Limitations
Checklist	<p><i>Please check to indicate if you have ever had the following conditions (check all that apply):</i></p> <ul style="list-style-type: none"> ○ <i>Diabetes</i> ○ <i>Kidney disease</i> ○ <i>Stroke</i> ○ <i>High blood pressure</i> ○ <i>Asthma</i> ○ <i>Heart attack</i> 	<ul style="list-style-type: none"> ● Provides limited information ● Checklists may not cover all the possible responses; in these instances, free text may be needed ● The use of checklists can impact data analysis, so careful consideration is needed when analyzing data from a multi-option variable
Dichotomous (two response options)	<p><i>Have you ever been diagnosed with glaucoma?</i></p> <ul style="list-style-type: none"> ○ <i>Yes</i> ○ <i>No</i> <p><i>I have been diagnosed with glaucoma</i></p> <ul style="list-style-type: none"> ○ <i>True</i> ○ <i>False</i> 	<ul style="list-style-type: none"> ● May force respondents to choose between options that may not be that simple, resulting in a response that doesn't completely capture their experience/feelings ● Limits the analysis that can be performed
Rankings	<p><i>Please rank the importance of the following characteristics of a treatment for lung cancer. (Fill in your rank order in the spaces provided using the numbers 1 through 5, with 1 indicating most important and 5 indicating least important.)</i></p>	<ul style="list-style-type: none"> ● Ranking can be a difficult task for respondents, particularly if there are several response options (e.g., >5) ● Rank order items can be

Response Option Type	Examples	Potential Limitations
Rating scales	<p data-bbox="402 268 841 428"> <input type="checkbox"/> <i>Treatment relieves symptoms</i> <input type="checkbox"/> <i>Treatment has few side effects</i> <input type="checkbox"/> <i>Treatment will increase survival</i> <input type="checkbox"/> <i>Treatment can be taken as a pill</i> <input type="checkbox"/> <i>Treatment can be taken monthly</i> </p> <p data-bbox="402 512 922 982"> <u>Numerical</u> <i>Please rate your pain at its worst in the last 24 hours.</i> <input type="radio"/> 0 (no pain) <input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3 <input type="radio"/> 4 <input type="radio"/> 5 <input type="radio"/> 6 <input type="radio"/> 7 <input type="radio"/> 8 <input type="radio"/> 9 <input type="radio"/> 10 (worst imaginable pain) </p> <p data-bbox="402 1050 922 1281"> <u>Verbal</u> <i>Please rate your pain at its worst in the last 24 hours.</i> <input type="radio"/> None <input type="radio"/> Mild <input type="radio"/> Moderate <input type="radio"/> Severe </p> <p data-bbox="402 1318 938 1520"> <i>How often have you had pain during the past week?</i> <input type="radio"/> Not at all <input type="radio"/> A little <input type="radio"/> Quite a bit <input type="radio"/> All the time </p>	<p data-bbox="1019 268 1312 365">difficult to analyze statistically and relate to other variables</p> <ul data-bbox="974 520 1321 1226" style="list-style-type: none"> • Decreased validity with extremes of age, e.g., young children (numerical) • Limited number of response categories (verbal) • Decreased validity in illiterate patients (verbal) • Although distances between verbal descriptors on verbal rating scales appear equidistant, the actual observed distances may vary (verbal) • Only rank-order inferences can be made about the relative differences between two or more ratings (verbal)
Visual analog scale	<p data-bbox="402 1562 909 1629"> <i>How severe has your abdominal pain been today? (Place a mark(1) on the line below)</i> </p> <div data-bbox="407 1663 907 1768" style="border: 1px solid black; padding: 5px; margin: 10px 0;"> <p data-bbox="435 1705 889 1755"> No pain Worst imaginable pain </p> </div>	<ul data-bbox="974 1570 1305 1869" style="list-style-type: none"> • False sense of precision • Cannot be administered verbally • Higher rates of missing data (Dworkin et al., 2005; Hawker et al., 2011) • Inconsistencies with the length of VAS line

537 You should consider the following factors to improve the validity of the respondents' response to
538 questions:

- 539 • Comprehension of question
- 540 • Knowledge to answer the question
- 541 • Social desirability (e.g., questions are administered in an appropriate setting in relation to
542 the sensitivity of the topic)
- 543 • Applicability of the content (although sometimes a not applicable response is also needed
544 for the question)
- 545 • Relevant response options (e.g., if a question is asking about pain medication but does
546 not include a response option for those who are not taking pain medications)

547
548 The ordering of questions in a survey/questionnaire is also important. The way a person
549 responds to a question can be influenced by earlier questions (e.g., priming or the respondent is
550 carrying over thoughts from the previous question to interpret the next question).

551
552 Priming can be problematic in survey research. Some ways to avoid priming include:

- 553 • Order questions deliberately
- 554 • Appropriate spacing of questions (separate topics into different pages or electronic
555 screens)
- 556 • Use clearly defined questions (provide instructions on what the question is to address)
- 557 • Randomize the order of questions

558
559 Once you have drafted questions and determined the order of questions, it may be helpful to have
560 them reviewed in a small subset of your study population prior to pre-testing them, if resources
561 are available, to identify any potential problematic questions.

562
563 When the survey/questionnaire is designed and nearly ready for use, pre-testing the questions is
564 an important step to find out if the data collection protocols and *instrument* can work
565 realistically.

566 **V. MIXED METHODS**

567
568 Mixed methods research is where both qualitative and quantitative methods are used. Refer to
569 **Sections III and IV** for how best to operationalize the respective method. For additional details
570 on mixed methods, refer to [Section III C of Guidance 1](#).

571 **VI. CONCLUSIONS**

572
573 This document has provided an overview of best practices of methods to collect what is most
574 important to patients related to the burden of disease and treatment, and benefits and risks in
575 patients' disease management to inform medical product development and regulatory decision
576 making. The proposed best practices presented serve only as a basis for dialogue in the evolving
577 and growing area of the *science of patient input*.

578

579 **VII. REFERENCES**

- 580 Cooper, C. J., Cooper, S. P., Del Junco, D. J., Shipp, E. M., Whitworth, R., & Cooper, S. R.
581 (2006). Web-based data collection: detailed methods of a questionnaire and data
582 gathering tool. *Epidemiologic Perspectives & Innovations*, 3(1), 1.
- 583 Creswell, JW, 2013, Qualitative inquiry and research design: Choosing among five approaches,
584 830 Los Angeles: SAGE Publications, Inc.
585
- 586 Dixon, C. S. (2015). Interviewing Adolescent Females in Qualitative Research. *The Qualitative*
587 *Report*, 20(12), 2067-2077. Retrieved from <http://nsuworks.nova.edu/tqr/vol20/iss12/12>.
- 588 Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core
589 outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*
590 2005;113:9–19.
591
- 592 FDA. (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to
593 Support Labeling Claims. *Guidance for Industry*. Retrieved March 15, 2018, from
594 [https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidanc](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf)
595 [es/UCM193282.pdf](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf)
596
- 597 Gibbs, G. R. (2007). Qualitative Research kit: Analyzing qualitative data. London, England:
598 SAGE Publications Ltd
599
- 600 Harkness, J. A. (2003). Questionnaire translation. In J. A. Harkness, F. van de Vijver, & P. Ph.
601 Mohler (Eds.), *Cross-cultural survey methods* (pp. 35-56). Hoboken, NJ: John Wiley & Son
602
- 603 Harkness, J. A. (2008). Comparative survey research: Goals and challenges. In E. D. de Leeuw,
604 J. J. Hox, & D. A. Dillman (Eds.), *International handbook of survey methodology* (pp. 56-
605 77). New York/London: Lawrence Erlbaum Associates
606
- 607 Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain
608 (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ),
609 Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short
610 Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant
611 Osteoarthritis Pain (ICOAP). *Arthritis Care Res* (Hoboken) 2011;63:S240–52.
612
- 613 Kawulich, Barbara B. (2005). Participant Observation as a Data Collection Method. *Forum*
614 *Qualitative Sozialforschung / Forum: Qualitative Social Research*, 6(2), Art.
615 43, <http://nbn-resolving.de/urn:nbn:de:0114-fqs0502430>.
- 616 Keeney, S, McKenna H, & Hasson F (2010). The Delphi technique in nursing and health
617 research, John Wiley & Sons.
618
- 619 Krueger, RA and Casey MA (2008). *Focus Groups: A practical guide for applied research*, 4th
620 Edition, Thousand Oaks, CA: SAGE Publications, Inc.
- 621 Leung, F.-H., & Savithiri, R. (2009). Spotlight on focus groups. *Canadian Family Physician*,
622 55(2), 218–219.
623

624 Mediciens San Frontieres (MSF) (2002). A guide to using qualitative research methodology 918
625 (accessible
626 at [https://evaluation.msf.org/sites/evaluation/files/a_guide_to_using_qualitative_research](https://evaluation.msf.org/sites/evaluation/files/a_guide_to_using_qualitative_research_methodology.pdf)
627 [methodology.pdf](https://evaluation.msf.org/sites/evaluation/files/a_guide_to_using_qualitative_research_methodology.pdf)).
628

629 National Collaborating Centre for Infectious Diseases. 2016, More than just numbers: Exploring
630 the concept of “burden of disease” NCCID Project No. 274.
631

632 Paterson, B., Bottorff, J., & Hewatt, R. (2003). Blending observational methods: Possibilities,
633 strategies, and challenges. *International Journal of Qualitative Methods*, 2 (1). Article 3.
634 Retrieved June 6, 2017 from [http://www.ualberta.ca/~iiqm/backissues/2_1/](http://www.ualberta.ca/~iiqm/backissues/2_1/html/patersonetal.html)
635 [html/patersonetal.html](http://www.ualberta.ca/~iiqm/backissues/2_1/html/patersonetal.html)
636

637 Jones, DS, Podolsky, SH & Greene, JA. 2012, The Burden of Disease and the Changing Task of
638 Medicine, *New England Journal of Medicine*, 366:2333-2338.
639

640 Schutt RK (2015). *Investigating the Social World: The Process and Practice of Research* (8th
641 ed.). Thousand Oaks, CA: Sage Publications, Inc.
642

643 Survey Research Center. (2016). *Guidelines for Best Practice in Cross-Cultural Surveys*. Ann
644 Arbor, MI: Survey Research Center, Institute for Social Research, University of
645 Michigan. Retrieved July, 03, 2018, from <http://www.ccsr.isr.umich.edu/>
646

647 Yin, RK (2016). *Qualitative research from start to finish*, New York: The Guilford Press.
648

649 Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P et al. (2005).
650 ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice
651 for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes
652 (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural
653 Adaptation. *Value Health*, 8(2):94-104.